(Q38256874)

1 September 2017

1 reference

title

Recent clinical trials for the etiological treatment of chronic chagas disease: advances, challenges and perspectives (English)

1 reference

1 September 2017

0 references

Julio A Urbina

1

1 reference

1 September 2017

publication date

13 November 2014

1 reference

The Journal of Eukaryotic Microbiology

1 September 2017

published in

1 reference

1 September 2017

volume

62

1 reference

1 September 2017

issue

1

1 reference

1 September 2017

page(s)

149-156

1 reference

Chronic human infection with Trypanosoma cruzi drives CD4+ T cells to immune senescence

1 September 2017

cites work

1 reference

A 9,000-year record of Chagas' disease

21 January 2018

1 reference

New vaccines for neglected parasitic diseases and dengue

21 January 2018

1 reference

Immunological control of Trypanosoma cruzi infection and pathogenesis of Chagas' disease.

21 January 2018

1 reference

Recent Developments in Sterol 14-demethylase Inhibitors for Chagas Disease.

21 January 2018

1 reference

Drug-induced cure drives conversion to a stable and protective CD8+ T central memory response in chronic Chagas disease

21 January 2018

1 reference

New, combined, and reduced dosing treatment protocols cure Trypanosoma cruzi infection in mice

21 January 2018

1 reference

Blood culture and polymerase chain reaction for the diagnosis of the chronic phase of human infection with Trypanosoma cruzi

21 January 2018

1 reference

Nova entidade morbida do homem: rezumo geral de estudos etiolojicos e clinicos

21 January 2018

1 reference

High throughput selection of effective serodiagnostics for Trypanosoma cruzi infection

21 January 2018

1 reference

Comparison of Trypanosoma cruzi detection by PCR in blood and dejections of Triatoma infestans fed on patients with chronic Chagas disease.

21 January 2018

1 reference

Chronic phase of Chagas disease: why should it be treated? A comprehensive review

21 January 2018

1 reference

Benznidazole and posaconazole in experimental Chagas disease: positive interaction in concomitant and sequential treatments

21 January 2018

1 reference

Phase 1b study of new posaconazole tablet for prevention of invasive fungal infections in high-risk patients with neutropenia

21 January 2018

1 reference

Efficacy of benznidazol treatment for asymptomatic chagasic patients from state of Rio Grande do Sul evaluated during a three years follow-up.

21 January 2018

1 reference

Short-term follow-up of chagasic patients after benzonidazole treatment using multiple serological markers.

21 January 2018

1 reference

Absence of CD4+ T lymphocytes, CD8+ T lymphocytes, or B lymphocytes has different effects on the efficacy of posaconazole and benznidazole in treatment of experimental acute Trypanosoma cruzi infection

21 January 2018

1 reference

Susceptibility and natural resistance of Trypanosoma cruzi strains to drugs used clinically in Chagas disease

21 January 2018

1 reference

The unfinished public health agenda of chagas disease in the era of globalization

21 January 2018

1 reference

Chagas disease in Spain, the United States and other non-endemic countries

21 January 2018

1 reference

Diagnosis of Chagas disease: what has been achieved? What remains to be done with regard to diagnosis and follow up studies?

21 January 2018

1 reference

Commentary: Chagas disease: 100 years since discovery and lessons for the future

21 January 2018

1 reference

The role of parasite persistence in pathogenesis of Chagas heart disease

21 January 2018

1 reference

The neglected tropical diseases of Latin America and the Caribbean: a review of disease burden and distribution and a roadmap for control and elimination

21 January 2018

1 reference

Modulation of autoimmunity by treatment of an infectious disease

21 January 2018

1 reference

Autoimmunity in chagas disease cardiomyopathy: Fulfilling the criteria at last?

21 January 2018

1 reference

Single-dose phase I study to evaluate the pharmacokinetics of posaconazole in new tablet and capsule formulations relative to oral suspension

21 January 2018

1 reference

A new solid oral tablet formulation of posaconazole: a randomized clinical trial to investigate rising single- and multiple-dose pharmacokinetics and safety in healthy volunteers

21 January 2018

1 reference

Changes in Trypanosoma cruzi-specific immune responses after treatment: surrogate markers of treatment efficacy

21 January 2018

1 reference

Global economic burden of Chagas disease: a computational simulation model

21 January 2018

1 reference

Posttherapeutic cure criteria in Chagas' disease: conventional serology followed by supplementary serological, parasitological, and molecular tests.

21 January 2018

1 reference

Pathogenesis of chronic Chagas heart disease

21 January 2018

1 reference

The BENEFIT trial: testing the hypothesis that trypanocidal therapy is beneficial for patients with chronic Chagas heart disease

21 January 2018

1 reference

Apolipoprotein A-I truncations in Chagas disease are caused by cruzipain, the major cysteine protease of Trypanosoma cruzi

21 January 2018

1 reference

Randomized trial of posaconazole and benznidazole for chronic Chagas' disease.

21 January 2018

1 reference

Preclinical monitoring of drug association in experimental chemotherapy of Chagas' disease by a new HPLC-UV method

21 January 2018

1 reference

Pharmacokinetics of SCH 56592, a new azole broad-spectrum antifungal agent, in mice, rats, rabbits, dogs, and cynomolgus monkeys

21 January 2018

1 reference

CD8+ T cells in Trypanosoma cruzi infection

21 January 2018

1 reference

Successful treatment with posaconazole of a patient with chronic Chagas disease and systemic lupus erythematosus

21 January 2018

1 reference

Biological markers for evaluating therapeutic efficacy in Chagas disease, a systematic review.

21 January 2018

1 reference

Challenges and opportunities for primary, secondary, and tertiary prevention of Chagas' disease

21 January 2018

1 reference

Posaconazole versus Benznidazole for Chronic Chagas' Disease

21 January 2018

1 reference

Eliminating Chagas disease: challenges and a roadmap

21 January 2018

1 reference

New, improved treatments for Chagas disease: from the R&D pipeline to the patients

21 January 2018

1 reference

Serum biomarkers predictive of cure in Chagas disease patients after nifurtimox treatment

21 January 2018

1 reference

Parasite persistence in the aetiology of Chagas disease

21 January 2018

1 reference

The challenges of Chagas Disease-- grim outlook or glimmer of hope

21 January 2018

1 reference

Pharmacokinetics, safety, and efficacy of posaconazole in patients with persistent febrile neutropenia or refractory invasive fungal infection

21 January 2018

1 reference

Chemotherapy of Chagas' disease: the how and the why.

21 January 2018

1 reference

Ergosterol biosynthesis and drug development for Chagas disease

21 January 2018

1 reference

Specific chemotherapy of Chagas disease: relevance, current limitations and new approaches

21 January 2018

1 reference

Towards a paradigm shift in the treatment of chronic Chagas disease.

21 January 2018

1 reference

Etiological treatment of chronic Chagas disease: neglected 'evidence' by evidence-based medicine

21 January 2018

1 reference

Impact of aetiological treatment on conventional and multiplex serology in chronic Chagas disease

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1111/JEU.12184

1 reference

1 September 2017

1 reference